BiotechTube

MNPR-101-PCTA-177Lu

Pre-clinicalActive
0 views this week 0 watching💤 Quiet
Interest: 20/100
20
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cancer

Conditions

Cancer, Solid Tumor, Solid Tumor Cancer, Oncology, uPAR-positive Solid Tumor, Urokinase Plasminogen Activator Receptor-positive Solid Tumor

Trial Timeline

— → —

NCT ID
NCT06980519

About MNPR-101-PCTA-177Lu

MNPR-101-PCTA-177Lu is a pre-clinical stage product being developed by Monopar Therapeutics for Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT06980519. Target conditions include Cancer, Solid Tumor, Solid Tumor Cancer.

What happened to similar drugs?

20 of 20 similar drugs in Cancer were approved

Approved (20) Terminated (4) Active (0)
✅arzoxifeneEli LillyApproved
✅EnzalutamideAstellas PharmaApproved
✅EnzalutamideAstellas PharmaApproved
✅Enzalutamide + Androgen deprivation therapy (ADT)Astellas PharmaApproved
✅Enzalutamide + Abiraterone + Placebo for Enzalutamide + PrednisoneAstellas PharmaApproved
✅EnzalutamideAstellas PharmaApproved
✅Enzalutamide + FlutamideAstellas PharmaApproved

Hype Score Breakdown

Clinical
3
Activity
12
Company
5
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT06980519Pre-clinicalActive
NCT06617169Phase 1Recruiting

Competing Products

20 competing products in Cancer

See all competitors
ProductCompanyStageHype Score
mFOLFOX regimen + MitazalimabAlligator Bioscience ABPhase 2/3
35
Intratumoral Mitazalimab + Intratumoral NivolumabAlligator Bioscience ABPhase 1
26
mRNA-2416ModernaPhase 2
0
Doxorubicin Hydrochloride Liposome InjectionDr. Reddy's LaboratoriesPhase 1
26
E7389EisaiPhase 1
29
VeliparibAbbViePhase 2
27
AK-105AkesoPhase 1
29
XL820ExelixisPhase 1
26
LymphoseekNavidea BiopharmaceuticalsPhase 3
30
LymphoseekNavidea BiopharmaceuticalsPhase 3
30
ALT-P7 (HM2-MMAE)AlteogenPhase 1
29
pegylated liposomal doxorubicin (PLD) + PD-1CSPC Pharmaceutical Group LimitedPhase 2
31
Biomarkers blood, urine and microbiota samplesEli LillyPre-clinical
30
gemcitabine + paclitaxel + bevacizumabEli LillyPhase 2
35
pemetrexedEli LillyPhase 2
27
LY3300054 + PrexasertibEli LillyPhase 1
29
BBP-398 with nivolumabBridgeBio PharmaPhase 1
18
Cetuximab + Oxaliplatin + CapecitabineEli LillyPhase 2
35
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
27
Gemcitabine + Adriamycine + PaclitaxelEli LillyPhase 2
35